An immune globulin, or antibody, is a large protein your immune system uses to identify foreign objects. It recognizes a specific molecule on a pathogen called an antigen. Immune globulins are responsible for a wide range of functions.
Intravenous immunoglobulin (IVIG) therapy is a treatment in which an intravenous infusion of immunoglobulin is administered to a patient. The aim is to maintain blood levels of Ig above a predetermined level. Typically, the patient needs three or four treatments per week.
Immunoglobulins are proteins the immune system produces that target bacterial and viral particles. Human immunoglobulin G (IgG) is a monomeric type of immunoglobulin. There are also several subclasses of IgG, each of which targets different pathogens.
Anti-D immunoglobulins (AdD) are antibodies that recognize a certain antigen. They are produced in plasma cells and have different biological and clinical activities. For example, their glycosylation influences the structure and function of AdD immunoglobulins. Glycosylation is defined by the cells that produce it and may contribute to their clinical or biological activity.
Rho(D) immunoglobulin is used to prevent and treat RhD isoimmunization in pregnant women and people who are Rh-positive. It is commonly given during pregnancy and after childbirth. It may also be given to people who have received RhD-positive blood.
In phase III clinical study, the investigational drug anifrolumab reversed disease-associated neutropenia, lymphopenia, and thrombocytopenia. In addition, the treatment improved the quality of life for patients with HIV and AIDS. The safety and efficacy of anifrolumab were assessed through the monitoring of AEs (adverse events), clinical laboratory tests, and immunogenicity. Patients were monitored monthly for a minimum of three years. Non-serious AEs were recorded during the first year of the study, while serious AEs were recorded at each visit during the second and third years. Serious AEs included hepatic dysfunction, hypersensitivity, and infections, including anaphylaxis and vasculitis.
Ansuvimab is an immunoglobulin inhibitor with an extended half-life. It works by mutating the Fc region residues at the FcRn-Fc interface. This increases the half-life of IgG in circulation.